López Ongil S L, Saura M, Lamas S, Rodriguez Puyol M, Rodriguez Puyol D
Department of Physiology, Alcalá de Henares University, Madrid, Spain.
Exp Nephrol. 1996 Jan-Feb;4(1):37-42.
Erythropoietin (rHuEPO)-induced hypertension represents a clinical problem in hemodialysis units. However, the underlying molecular mechanisms of this side effect are still unclear. In order to assess the potential participation of the endothelial-derived vasoactive factors, nitric oxide and endothelin-1, bovine aortic endothelial cells were incubated in the presence of rHuEPO. The latter (0.1-10 U/ml, 1-24 h) did not modify the synthesis of nitric oxide and endothelin-1 or the expression of nitric oxide synthase and pre-pro-endothelin-1 mRNAs. These results suggest that endothelial-derived vasoactive factors are not a key component in the hypertensive response observed in certain patients after the administration of rHuEPO.
